The latest readout from INAVO120 marks the first time a PI3K-inhibiting targeted treatment has shown an overall survival advantage.

The company calls the candidate the "first known investigational allosteric, pan-mutant and isoform-selective inhibitor of PI3Kα." There was also a 33% objective response rate across all patients ...

Despite its expensive valuation and declining estimates, we suggest investors hold LLY stock as the company boasts solid ...

ETX-636 preclinical data to be presented at the AACR annual meeting, showcasing superior potency and selectivity for all mutant forms of PI3Kα while sparing wildtype PI3Kα Mutant PI3Kα is a key ...

Scorpion's lead drug asset, a mutant-selective PI3Kα inhibitor known as STX-478, is currently in Phase 1/2 testing for the treatment of breast cancer and other solid tumors. Under the deal ...

The highlights included a potent KRAS inhibitor with impressive tumor growth inhibition in mouse models, a novel PI3Kα inhibitor demonstrating efficacy against key mutations, and a selective ...

Ensem Therapeutics Inc. has gained IND clearance from the FDA for ETX-636, a novel allosteric pan-mutant-selective PI3Kα inhibitor and degrader. A first-in-human trial will begin this quarter. The ...

BOULDER, Colo., May 06, 2025 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on developing novel precision medicines in oncology, today ...

"We are thrilled to present the first clinical data for our lead program, OKI-219, which is the only highly selective PI3Kα H1047R inhibitor molecule in the clinic,” said Nicholas Saccomano, Ph.D., ...

We also have leveraged our boron chemistry capabilities to identify multiple oncology candidates including potentially best-in-class inhibitors for ENPP1 and PI3Kα with our lead compound(s ...

We designed OKI-219 and our ongoing PIKture-01 trial to set a high bar for achieving considerable selectivity in targeting oncogenic PI3Kα H1047R. Late last year, we announced preliminary data ...